TIL
Adverse Drug Event
Leiden UniversityCell therapyPhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Adverse Drug Event cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Oliceridine University of Tennessee | Phase 4 | BB |
ERIBULIN MONOMETHANESULFONATE Oncologia Medica dell'Ospedale Fatebenefratelli | Phase 4 | BB |
Eloxatin Zhejiang University | Phase 3 | BB |
Capecitabine Zhejiang University | Phase 3 | BB |
Salovum Henrik Lindman | Phase 3 | B |
View all 9 →
Same molecule, other indications
TIL is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →